Related Experiment Video

Updated: Mar 7, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

Doubling Down on Mutant RAS Can MEK or Break Leukemia

Zuzana Tothova1, Benjamin L Ebert1

  • 1Brigham and Women's Hospital, Division of Hematology, Boston, MA 02115, USA; Dana Farber Cancer Institute, Department of Medical Oncology, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Cell
|February 25, 2017
PubMed

Insights

Researchers studied how KRAS mutations affect cancer cell growth and response to MEK inhibitors in acute myeloid leukemia. They found that the balance of mutant and normal KRAS can predict treatment effectiveness, suggesting a new biomarker.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • The RAS pathway is a crucial target in cancer therapy, but effective targeting remains a challenge.
  • KRAS mutations are common drivers in various cancers, including acute myeloid leukemia (AML).
  • Understanding the interplay between mutant and wild-type KRAS is essential for developing targeted therapies.

Purpose of the Study:

  • To investigate how the relative expression of mutant and wild-type KRAS influences clonal fitness in AML.
  • To determine the impact of KRAS expression levels on sensitivity to MEK inhibitors.
  • To evaluate the potential of KRAS expression as a predictive biomarker for MEK inhibitor therapy in AML.

Main Methods:

  • Utilized a KrasG12D mutant AML mouse model.
  • Quantified the relative expression of mutant and wild-type KRAS alleles.
  • Assessed clonal fitness and tumor growth under different KRAS expression scenarios.
  • Evaluated the response to MEK inhibitor treatment based on KRAS mutational status.

Main Results:

  • The ratio of mutant KRAS to wild-type KRAS significantly modulated clonal fitness in the AML model.
  • Differential KRAS expression levels correlated with varying sensitivity to MEK inhibitors.
  • Specific KRAS expression profiles were identified in relation to treatment response.

Conclusions:

  • The relative expression of mutant and wild-type KRAS is a key determinant of clonal fitness and MEK inhibitor sensitivity in KrasG12D AML.
  • KRAS expression levels hold promise as a predictive biomarker for guiding MEK inhibitor therapy in AML patients.
  • Further clinical validation is warranted to establish KRAS expression as a reliable biomarker in oncology.

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

788
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

878

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.4K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.6K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
17.4K